<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002798</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01834</org_study_id>
    <secondary_id>2961</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <secondary_id>CDR0000064883</secondary_id>
    <nct_id>NCT00002798</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome</brief_title>
  <official_title>A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Randomized phase III trial to compare the effectiveness of different chemotherapy regimens
      with or without bone marrow transplantation in treating children who have acute myelogenous
      leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop
      cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone
      marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and
      kill more cancer cells. It is not yet known which treatment regimen is more effective for
      acute myelogenous leukemia or myelodysplastic syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Increase the remission induction rate to greater than 85% in children with untreated acute
      myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) by replacing daunorubicin (DNR)
      with idarubicin (IDA) in intensively timed DCTER chemotherapy (dexamethasone, cytarabine
      (ARA-C), thioguanine, etoposide, and daunorubicin) in the first 4 days of each course.

      Increase the remission rate further by comparing the efficacy of consolidation chemotherapy
      with intensively timed IDA DCTER/DCTER vs fludarabine (FAMP), ARA-C, and IDA in maintaining
      remission and in achieving remission in patients with M2 disease (5%-29% blasts in marrow) at
      the end of induction chemotherapy.

      Compare overall survival, event-free survival, and disease-free survival in patients who
      receive consolidation with IDA DCTER/DCTER vs FAMP, ARA-C, and IDA.

      Compare overall survival, event-free survival, and disease-free survival in patients
      receiving intensification with the Capizzi II regimen (high-dose ARA-C and asparaginase) vs
      those receiving a matched-related allogeneic bone marrow transplantation.

      Compare overall survival, event-free survival, and disease-free survival in patients treated
      with interleukin-2 (IL-2) vs standard follow up care after Capizzi II intensification.

      Determine whether multichannel flow cytometry detection of residual AML on a companion
      biologic study protocol CCG-B942 predicts outcome, and determine whether any of these
      treatment regimens eliminates minimal residual disease more effectively than another.

      Register all patients with MDS treated or followed at CCG institutions and capture their
      biologic, historical and outcome data.

      Determine, on a companion biologic study protocol CCG-B972, whether levels of IL-2 soluble
      receptor (sIL-2R) and absolute lymphocyte count (ALC) before, during, and after therapy
      correlates with outcome.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      center, diagnosis (acute myelogenous leukemia vs other), and response to induction (partial
      vs complete remission). After induction, patients with M1/M2 marrow are randomized to arm I
      or II. Patients in complete remission after consolidation who have an HLA-identical or
      1-antigen mismatched sibling or parent donor are randomly assigned to the allogeneic bone
      marrow transplantation (AlBMT) regimen; all others in complete remission are nonrandomly
      assigned to the Capizzi II regimen, then are randomly assigned to arms III or IV. Patients
      with refractory anemia (RA) or RA with ringed sideroblasts with indolent disease may be
      registered and followed. Other patients with myelodysplastic syndromes may receive 2961
      chemotherapy or go directly to AlBMT. Patients with chloromas (granulocytic sarcomas) receive
      optional radiotherapy on arm V.

      Induction: Patients receive idarubicin IV over 30 minutes on days 0-3, cytarabine and
      etoposide IV continuously on days 0-3, and oral thioguanine twice a day and oral
      dexamethasone 3 times a day on days 0-3. Patients then begin course 2, which consists of
      cytarabine, etoposide, thioguanine, and dexamethasone on days 10-13, daunorubicin IV
      continuously on days 10-13, and filgrastim (G-CSF) subcutaneously (SC) beginning on day 16
      and continuing until blood counts recover. Patients also receive CNS prophylaxis/therapy
      consisting of cytarabine intrathecally (IT) on days 0 and 14 (if no CNS disease at entry) or
      on days 0, 5, and 7 (if CNS disease present at entry). Disease is reassessed on day 28-42.
      Patients with M1 or M2 marrow proceed to consolidation while those with M3 marrow or
      progressive disease go off study.

      Consolidation:

      Arm I: Patients receive treatment as in induction therapy, plus G-CSF SC beginning on day 16
      and continuing until blood counts recover. If CSF is clear by day 10 of induction, patients
      receive cytarabine IT on days 0, 10, and 35. If CSF is not clear, patients receive triple
      intrathecal therapy (TIT; cytarabine, hydrocortisone, methotrexate) on days 0 and 10.

      Arm II: Patients receive fludarabine IV over 24 hours on days 0 and 1, cytarabine IV over 72
      hours on days 2-4, and idarubicin IV over 15 minutes on days 0-2. G-CSF begins on day 6 and
      continues until blood counts recover. Patients also receive TIT on days -1 and 7, if CSF is
      not clear on day 10 of induction. Patients on both arms are reassessed on day 35. Those
      patients with M1 marrow proceed to intensification; all others are removed from the study.

      Intensification:

      Capizzi II regimen: Course 1: Patients receive cytarabine IV over 3 hours every 12 hours on
      days 0, 1, 7, and 8 and asparaginase IM on days 1 and 8. Course 2: Patients also receive
      cytarabine IT or TIT on days 0, 7, and 14.AlBMT regimen: Therapy begins within 2-8 weeks of
      hematologic recovery. Patients may receive interim therapy consisting of oral thioguanine for
      about 2 weeks. Patients then receive oral busulfan every 6 hours on days -9 to -6 and
      cyclophosphamide IV over 1 hour on days -5 to -2. AlBMT is infused over 4 hours beginning
      36-48 hours after the last dose of cyclophosphamide. Patients in complete remission after
      completing the Capizzi II regimen proceed to maintenance therapy on arm III.

      Arm III: Patients receive interleukin-2 IV continuously on days 1-4 and 9-18.

      Arm IV: No further treatment.

      Arm V: Patients undergo radiotherapy to the chloroma 5 days a week for 2 weeks.

      Patients are followed monthly for 18 months, every 3 months for 1 year, and then every 6
      months until 5 years from diagnosis.

      PROJECTED ACCRUAL: Approximately 880 patients with de novo acute myelogenous leukemia will be
      accrued for this study within 4 years. It is expected that 178 patients per year will be
      randomly assigned for consolidation, that 39 patients per year will undergo allogeneic bone
      marrow transplantation while 120 patients per year will receive chemotherapy as
      intensification, and that 102 patients per year will be randomly assigned for
      polychemotherapy immunomodulation. An additional 80 patients with myelodysplastic syndromes
      will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1996</start_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of patients achieving remission rate during induction therapy</measure>
    <time_frame>Up to 42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients dying or with residual disease during induction therapy</measure>
    <time_frame>Up to 42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to marrow recovery (induction phase)</measure>
    <time_frame>Up to 42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of toxicities, including infectious complications (induction phase)</measure>
    <time_frame>Up to 42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Marrow status</measure>
    <time_frame>At 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of blasts</measure>
    <time_frame>At the end of induction therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission at the end of consolidation therapy</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival following consolidation</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival following consolidation</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (intensification)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>EFS (intensification)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">880</enrollment>
  <condition>Childhood Acute Erythroleukemia (M6)</condition>
  <condition>Childhood Acute Megakaryocytic Leukemia (M7)</condition>
  <condition>Childhood Acute Monoblastic Leukemia (M5a)</condition>
  <condition>Childhood Acute Monocytic Leukemia (M5b)</condition>
  <condition>Childhood Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Childhood Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Childhood Acute Myelomonocytic Leukemia (M4)</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Refractory Anemia</condition>
  <condition>Refractory Anemia With Excess Blasts</condition>
  <condition>Refractory Anemia With Excess Blasts in Transformation</condition>
  <condition>Refractory Anemia With Ringed Sideroblasts</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <condition>Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies</condition>
  <arm_group>
    <arm_group_label>Arm I (combination chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive treatment as in induction therapy, plus G-CSF SC beginning on day 16 and continuing until blood counts recover. If CSF is clear by day 10 of induction, patients receive cytarabine IT on days 0, 10, and 35. If CSF is not clear, patients receive triple intrathecal therapy (TIT; cytarabine, hydrocortisone, methotrexate) on days 0 and 10.
See Detailed Description</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (combination chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine IV over 24 hours on days 0 and 1, cytarabine IV over 72 hours on days 2-4, and idarubicin IV over 15 minutes on days 0-2. G-CSF begins on day 6 and continues until blood counts recover. Patients also receive TIT on days -1 and 7, if CSF is not clear on day 10 of induction. Patients on both arms are reassessed on day 35. Those patients with M1 marrow proceed to intensification; all others are removed from the study.
Intensification: See Detailed Description</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (combination chemotherapy, aldesleukin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive interleukin-2 IV continuously on days 1-4 and 9-18.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (combination chemotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No further treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm V (combination chemotherapy, radiotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo radiotherapy to the chloroma 5 days a week for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
    <arm_group_label>Arm II (combination chemotherapy)</arm_group_label>
    <other_name>ASNase</other_name>
    <other_name>Colaspase</other_name>
    <other_name>Crasnitin</other_name>
    <other_name>Elspar</other_name>
    <other_name>L-ASP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
    <arm_group_label>Arm I (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm III (combination chemotherapy, aldesleukin)</arm_group_label>
    <arm_group_label>Arm IV (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm V (combination chemotherapy, radiotherapy)</arm_group_label>
    <other_name>Cerubidin</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>daunomycin hydrochloride</other_name>
    <other_name>daunorubicin</other_name>
    <other_name>RP-13057</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>Arm II (combination chemotherapy)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic hydrocortisone</intervention_name>
    <arm_group_label>Arm I (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy)</arm_group_label>
    <other_name>Aeroseb-HC</other_name>
    <other_name>Barseb HC</other_name>
    <other_name>Cetacort</other_name>
    <other_name>Cort-Dome</other_name>
    <other_name>Cortef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <arm_group_label>Arm I (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy)</arm_group_label>
    <other_name>bone marrow therapy, allogeneic</other_name>
    <other_name>bone marrow therapy, allogenic</other_name>
    <other_name>transplantation, allogeneic bone marrow</other_name>
    <other_name>transplantation, allogenic bone marrow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
    <arm_group_label>Arm V (combination chemotherapy, radiotherapy)</arm_group_label>
    <other_name>3D conformal radiation therapy</other_name>
    <other_name>3D-CRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm III (combination chemotherapy, aldesleukin)</arm_group_label>
    <arm_group_label>Arm IV (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm V (combination chemotherapy, radiotherapy)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV or IT</description>
    <arm_group_label>Arm I (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm III (combination chemotherapy, aldesleukin)</arm_group_label>
    <arm_group_label>Arm IV (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm V (combination chemotherapy, radiotherapy)</arm_group_label>
    <other_name>ARA-C</other_name>
    <other_name>arabinofuranosylcytosine</other_name>
    <other_name>arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm III (combination chemotherapy, aldesleukin)</arm_group_label>
    <arm_group_label>Arm IV (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm V (combination chemotherapy, radiotherapy)</arm_group_label>
    <other_name>4-demethoxydaunorubicin</other_name>
    <other_name>4-DMDR</other_name>
    <other_name>DMDR</other_name>
    <other_name>IDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm III (combination chemotherapy, aldesleukin)</arm_group_label>
    <arm_group_label>Arm IV (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm V (combination chemotherapy, radiotherapy)</arm_group_label>
    <other_name>Aeroseb-Dex</other_name>
    <other_name>Decaderm</other_name>
    <other_name>Decadron</other_name>
    <other_name>DM</other_name>
    <other_name>DXM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm III (combination chemotherapy, aldesleukin)</arm_group_label>
    <arm_group_label>Arm IV (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm V (combination chemotherapy, radiotherapy)</arm_group_label>
    <other_name>6-TG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm III (combination chemotherapy, aldesleukin)</arm_group_label>
    <arm_group_label>Arm IV (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm V (combination chemotherapy, radiotherapy)</arm_group_label>
    <other_name>EPEG</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Arm I (combination chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (combination chemotherapy)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <arm_group_label>Arm III (combination chemotherapy, aldesleukin)</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>recombinant human interleukin-2</other_name>
    <other_name>recombinant interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <arm_group_label>Arm II (combination chemotherapy)</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed previously untreated acute myeloid leukemia (AML) in patients
             1 month to 21 years of age

               -  Infants under 1 month with progressive disease eligible

                    -  Supportive care may be given to confirm that the leukemia is not regressing
                       prior to entry

               -  No acute promyelocytic leukemia (FAB M3)

               -  No acute undifferentiated leukemia (FAB M0)

          -  Histochemical verification of AML required by the following stains:

               -  Wright or Giemsa

               -  Peroxidase

               -  PAS

               -  Chloroacetate esterase

               -  Sudan black

               -  Nonspecific esterase (NSE) with and without fluoride (NaF) inhibition

               -  Combined NSE/NaF and butyrate inhibition or diagnosis of megakaryoblasticleukemia
                  (FAB M7) should be supported by one of the following:

                    -  CD41 reactivity

                    -  Glycoprotein 1b reactivity

                    -  Factor VIII-related antigen reactivity

                    -  Platelet peroxidase on electron microscopy

          -  The following are also eligible:

               -  Myelodysplastic syndromes, including:

                    -  Refractory anemia (RA) *

                    -  RA with ringed sideroblasts (RARS) *

                    -  RA with excess blasts (RAEB)

                    -  RAEB in transformation (RAEBt)

                    -  Chronic myelomonocytic leukemia (CMML)

               -  AML with monosomy 7

               -  Granulocytic sarcoma (chloroma) with or without marrow involvement

               -  Mixed lineage leukemia with 2 morphologically defined populations provided the
                  predominant population is myeloid

          -  No Downs syndrome

          -  No juvenile chronic myelogenous leukemia

          -  No Fanconi's anemia

          -  No secondary AML

          -  Performance status - Not specified

          -  No prior anticancer chemotherapy

          -  Prior topical or inhaled steroids for nonmalignant conditions allowed

          -  No prior anticancer radiotherapy

          -  No prior antileukemic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Lange</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

